GLP-1s Explained · formblends network
An encyclopedia of incretin drugs: semaglutide (injection and tablets), tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide, orforglipron, retatrutide, survodutide, CagriSema and mazdutide. Mechanism and receptor profile, FDA approval dates, label dosing, pivotal trial numbers with PubMed ids, and side-effect rates from the label's own table.
Interactive
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
Reading
Written for people doing the arithmetic themselves: where the mistakes happen, and how to check your own work.
Agents
The once-weekly GLP-1 receptor agonist behind Ozempic and Wegovy: how it works, every FDA approval from 2017 to the 7.2 mg dose in 2026, label dosing, STEP and SELECT numbers, and adverse-reaction rates from the label.
Updated September 4, 2026
Agents
How a peptide is taken by mouth, the three semaglutide tablets and why they are not interchangeable, the 25 mg Wegovy tablet approved in December 2025, OASIS 4 and PIONEER numbers, and label adverse-reaction rates.
Updated September 4, 2026
Agents
How tirzepatide differs from a pure GLP-1 drug, every FDA approval from May 2022 to the cardiovascular indication of August 2026, label dosing and missed-dose rules, SURMOUNT and SURPASS numbers, and adverse-reaction rates from the label.
Updated September 4, 2026
Agents
A non-peptide GLP-1 agonist taken as a daily tablet with no fasting rule, approved as Foundayo on 1 April 2026 for weight reduction: how it differs from oral semaglutide, label dosing and CYP3A4 rules, ATTAIN-1 and ACHIEVE-1 numbers, and label adverse-reaction rates.
Updated September 4, 2026
Guides
The physiology behind every entry on this site: what GLP-1 does, why the native hormone is useless as a drug, the three engineering tricks that made it last, what GIP, glucagon and amylin add, and how peptides differ from the new small molecule.
Updated September 4, 2026
Guides
How to read the status line on every entry: what an FDA approval is and is not, what phase 3 published means for availability, why a discontinued drug is still approved, and why compounded semaglutide and tirzepatide sit outside all of it.
Updated September 4, 2026
Browse
Every agent page follows one template: what the molecule is and which receptors it activates, every FDA approval with its date and application number, the dosing schedule exactly as the label states it, the pivotal trials with their PubMed ids and headline numbers, the adverse-reaction rates from the label's placebo-controlled table, the boxed warning, and the current status. A fact that could not be traced to one of those sources was left out.
Thirteen entries cover nine agents with an FDA approval on record (two of them discontinued) and four agents still in trials. Compounded semaglutide and tirzepatide, including the products FormBlends dispenses, are not FDA approved and are not interchangeable with the brand products described here; the label numbers on this site describe the approved products only.
From the FormBlends network
Sister sites